What is the PIRO score?

The PIRO score is a bedside severity index for adults with community-acquired pneumonia (CAP) who require intensive care unit (ICU) admission. The acronym summarizes four mechanistic domains: Predisposition, Insult, Response, and Organ dysfunction. Each domain contributes up to two points from binary criteria, yielding a total score from 0 to 8.

Unlike ward-based prognostic tools such as CURB-65 or the Pneumonia Severity Index, PIRO was developed specifically in critically ill CAP cohorts to capture host vulnerability, microbial burden, physiologic decompensation, and end-organ injury in a single additive framework. In the original derivation study, higher PIRO totals were associated with steep gradients in 28-day ICU mortality, and discrimination for death reportedly exceeded APACHE II and contemporaneous ATS/IDSA minor/major severity criteria in that population.

PIRO is a prognostic instrument. It does not define antibiotic choice, ventilator settings, or a treatment protocol. Clinicians use it to communicate expected course, align monitoring intensity, and support shared decision-making alongside culture data, imaging, and evolving physiology.

Clinical context: severe CAP in the ICU

Community-acquired pneumonia remains a leading cause of infection-related hospitalization and ICU admission worldwide. Patients who escalate to the ICU often have combinations of hypoxemic respiratory failure, septic shock, multilobar infiltrates, bacteremia, and acute kidney injury. Severity assessment in this setting must be rapid, repeatable at the bedside, and interpretable without proprietary software.

Traditional ICU scores (for example APACHE II) were not designed exclusively for pneumonia and may overweight chronic comorbidity while underemphasizing pneumonia-specific insults such as bacteremia or multilobar consolidation. PIRO was proposed as a pneumonia-focused alternative that still reflects systemic illness through shock, hypoxemia, renal failure, and ARDS.

This calculator implements the published eight-criterion model used on MDCalc and in Rello et al. (Crit Care Med 2009). Always document the time point at which criteria are assessed (for example at ICU admission versus 24 hours later), because scores are not static prognostic labels.

The P-I-R-O framework

PIRO organizes risk along a pathophysiologic sequence rather than as a single composite illness marker:

• Predisposition (P): baseline host factors that limit reserve before the pneumonia episode.
• Insult (I): markers of greater microbial or anatomic pulmonary injury.
• Response (R): early systemic and respiratory decompensation reflecting failed compensation.
• Organ dysfunction (O): established failure of kidney and lung parenchyma beyond isolated hypoxemia.

Each met criterion adds 1 point. Domain subscores (0–2 per letter) help teams see whether risk is driven primarily by chronic vulnerability, invasive infection, hemodynamic collapse, or established organ failure.

Predisposition (P): up to 2 points

Comorbidities: COPD or immunocompromised (1 point)

Award this point when the patient has chronic obstructive pulmonary disease and/or is immunocompromised by accepted clinical definitions. Immunocompromise may include therapeutic immunosuppression (high-dose corticosteroids, chemotherapy, biologics), hematologic malignancy, solid organ or stem-cell transplant, advanced HIV with immunologic suppression, or other states that materially increase infection susceptibility.

COPD reflects reduced pulmonary reserve and altered mucociliary clearance. Immunocompromise shifts pathogen spectrum and impairs host containment even after appropriate antibiotics. Either condition alone satisfies the criterion; both do not double the domain score because only one predisposition comorbidity slot exists in the published rule.

Age >70 years (1 point)

Award this point when chronological age exceeds 70 years at the time of assessment. Advanced age correlates with frailty, impaired immune senescence, delayed presentation, and higher baseline mortality in CAP cohorts. The threshold is a simple binary cut point from the derivation study rather than a continuous age-adjusted function.

Insult (I): up to 2 points

Bacteremia (1 point)

Award this point for positive blood cultures with a clinically plausible pathogen in the setting of pneumonia. Bacteremia signals higher bacterial load, possible hematogenous spread, and need for source control considerations. Contaminants and colonizers must be interpreted in clinical context; PIRO does not replace microbiology judgment.

Multilobar opacities on chest radiograph (1 point)

Award this point when imaging shows infiltrates, consolidation, or opacities involving more than one lobe on chest radiograph (or equivalent cross-sectional imaging when radiograph is unavailable, per local practice). Multilobar involvement implies greater affected lung mass, higher shunt physiology, and longer ventilatory support in many ICU CAP series.

Response (R): up to 2 points

Shock (1 point)

Award this point when the patient has shock defined as systolic blood pressure <90 mmHg or requirement for vasopressors to maintain adequate perfusion. This captures early cardiovascular failure in the sepsis spectrum complicating severe pneumonia. Transient hypotension that responds immediately to a fluid bolus still counts if it meets the criterion at assessment unless your local protocol explicitly documents otherwise.

Severe hypoxemia (1 point)

Award this point for severe hypoxemia as defined in the source cohort and common ICU practice. In bedside use this often corresponds to a low PaO₂/FiO₂ ratio (for example <250), high supplemental oxygen requirement, or need for high-flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation driven by refractory hypoxemia. Apply consistent institutional thresholds when comparing patients over time.

Organ dysfunction (O): up to 2 points

Acute renal failure (1 point)

Award this point for acute renal failure attributable to the acute illness, such as rising serum creatinine above baseline, oliguria, or need for renal replacement therapy when not already chronically dialyzed for end-stage kidney disease. Renal injury in severe CAP often reflects hypoperfusion, sepsis-associated acute kidney injury, or nephrotoxic exposures and portends longer ICU stay and higher mortality in observational data.

Acute respiratory distress syndrome (ARDS) (1 point)

Award this point when the patient meets ARDS by prevailing criteria (for example the Berlin definition: timing within one week of a known clinical insult, bilateral opacities not fully explained by effusions or collapse, respiratory failure not fully explained by cardiac failure, and PaO₂/FiO₂ stratification with appropriate PEEP). ARDS marks established alveolar-capillary injury beyond uncomplicated pneumonia and is associated with prolonged ventilation and ICU mortality.

Scoring summary

Domain	Criterion	Points if present
P Predisposition	COPD or immunocompromised	1
	Age >70 years	1
I Insult	Bacteremia	1
	Multilobar opacities on chest radiograph	1
R Response	Shock (SBP <90 mmHg or vasopressors)	1
	Severe hypoxemia	1
O Organ dysfunction	Acute renal failure	1
	ARDS	1

Total PIRO score = sum of all met criteria (range 0–8). Each domain contributes 0, 1, or 2 points.

Mortality risk strata (derivation ICU cohort)

In Rello et al., 28-day mortality in ICU CAP patients stratified by total score as follows. These figures describe the original single-center derivation cohort; recalibrate expectations with local outcomes when possible.

• 0–2 points (lower severity stratum): approximately 4% 28-day mortality. Lower cumulative PIRO burden. Continue standard ICU care, serial reassessment, and integration with CAP guidelines and other severity indices.
• 3–4 points (intermediate stratum): mortality between the low and high bands. Moderate predisposition, insult, response, and organ dysfunction. Heightened monitoring, early escalation planning, and goals-of-care discussions may be appropriate when aligned with the overall clinical picture.
• 5–8 points (higher severity stratum): approximately 76% 28-day mortality. Marked PIRO burden associated with substantially higher ICU mortality in the original study. Prioritize aggressive supportive care, specialist input, and candid prognosis discussions consistent with patient values.

Reported discrimination for 28-day mortality in the derivation analysis was strong (AUROC approximately 0.88), exceeding APACHE II and 2007 ATS/IDSA severity criteria in that dataset. External validation across hospitals, regions, and eras is advisable before applying population mortality percentages to individuals.

How PIRO compares with other CAP tools

CURB-65 and the Pneumonia Severity Index excel at emergency department triage and admission decisions for ward-level CAP. They are not tailored to ICU physiology, ventilator dependence, or ARDS.

APACHE II and related generic ICU scores summarize illness severity across diagnoses but may be cumbersome at the bedside and less pneumonia-specific.

ATS/IDSA minor and major criteria for severe CAP emphasize objective instability and organ failure but were not designed as a compact 0–8 additive mortality model in the ICU.

PIRO occupies a middle ground: pneumonia-specific, ICU-focused, and quick to calculate from routine clinical data. It complements, rather than replaces, sepsis bundles, culture-directed antibiotics, lung-protective ventilation, and fluid stewardship.

Practical uses in critical care

• Prognostic framing: communicate expected mortality bands to patients, surrogates, and consulting teams using calibrated language.
• Monitoring intensity: higher scores support closer nursing ratios, frequent arterial blood gas and lactate trending, and early nephrology or pulmonology involvement when indicated.
• Research and quality: risk-adjust comparisons of ICU CAP outcomes across time periods or centers when definitions are standardized.
• Trajectory checks: repeat scoring after major clinical transitions (intubation, dialysis initiation, new bacteremia) to document evolving risk, not only admission snapshots.

Higher PIRO scores correlate with prolonged ICU length of stay and mechanical ventilation in published analyses. No PIRO-specific treatment pathway exists; management follows severe CAP and sepsis standards, local antibiograms, and individualized goals of care.

When the score may not apply

• Non-ICU CAP: performance in ward patients or emergency departments may differ; do not extrapolate ICU mortality bands without validation.
• Hospital-acquired or ventilator-associated pneumonia: PIRO was derived in community-acquired ICU pneumonia.
• Atypical populations: immunocompromised hosts, pregnancy, or post-lung transplant CAP may have distinct trajectories not captured in the original cohort.
• Incomplete data: missing cultures, delayed imaging, or undocumented shock episodes distort scores.

Limitations and documentation tips

Single-center derivation limits generalizability. Binary thresholds simplify bedside use but sacrifice granularity (for example age 71 versus 69). Definitions of severe hypoxemia, renal failure, and ARDS require local consistency to avoid inter-observer drift.

PIRO does not incorporate biomarkers (procalcitonin, CRP), microbiology beyond bacteremia, nor antibiotic resistance patterns. It does not replace culture-directed therapy, source control, or ventilator protocols. Adjunctive therapies such as corticosteroids require guideline- and patient-specific justification beyond the numeric score.

When using this calculator, record which criteria were present, the assessment time, and whether management changed because of clinical findings independent of PIRO. Low scores do not exclude ventilatory support or vasopressors when bedside examination warrants them; high scores do not mandate limitation of care without patient values and reversible contributors addressed.

Using this CalcMD calculator

Select each criterion present at the time of evaluation. The tool computes the total score (0–8), domain subtotals for P, I, R, and O, and mortality risk stratum messaging aligned with the derivation cohort. Use the result as structured documentation and educational support, not as the sole basis for clinical decisions.